TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Stress-Reactivity and Cannabis Use in Cannabis-Using Older Adults

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SCREENING
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 50-80.~* Women must be \>1 year post-menopausal.~* English as a first/primary language.~* Functional visual and auditory acuity (aided or unaided) to complete tests.~* Capacity to independently provide informed consent and function at an intellectual level sufficient to allow completion of all instruments.~* Currently meets DSM-5 criteria for CUD or uses cannabis at least 4 days per week~* Consent to abstain from alcohol and cannabis use for \>12 hours prior to Study Visit (Day 0), and TSST (Day 8).~* Consent to abstain from all drugs other than cannabis or nicotine for the duration of the study.~Exclusion Criteria:~* Meet DSM-5 criteria for moderate or severe alcohol or substance use disorder (other than nicotine or cannabis) within the last 12 months.~* History of major neurocognitive disorder or developmental disorder per DSM-5.~* A Telephone Interview for Cognitive Status (TICS) score of less than or equal to 22.~* Significant or unstable medical condition/s that impact cognition as deemed by study investigators, such as active significant cardiac, cerebrovascular, neoplastic, infectious, or metabolic disease, or longstanding and intractable severe mental illness (e.g. schizophrenia spectrum disorder, bipolar disorder).~* Daily use of medications that adversely impact cognition in aging (i.e. anticholinergics and sedatives).~* Current suicidal or homicidal ideation/risk.~* Unable to complete/comply with procedures or pose threat to research staff.~* Standard MRI contraindications (e.g., implants, claustrophobia).~* Women who are pregnant, nursing, or of childbearing potential and not practicing and effective means of birth control.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Stress Induction (Type: EXPERIMENTAL): Participants completed the Trier Social Stress Test (TSST)
- No intervention (Type: NO_INTERVENTION): Participants did not complete the Trier Social Stress Test (TSST).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Sleep Study Results After Partial Intracapsular Tonsillectomy Versus Total Tonsillectomy

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* The medical records of 149 children who underwent partial intracapsular tonsillectomy and adenoidectomy at the State University of New York (SUNY) Downstate Medical Center or the Long Island College Hospital will be reviewed to identify children with positive preoperative polysomnography. 18 of those with positive preoperative studies will be randomly selected and offered participation in the study.~* Once enrolled, the participants will be matched by age, sex, time since procedure and polysomnography results (Apnea Hypopnea Index Index within 5) to 18 children who underwent traditional tonsillectomy and adenoidectomy (out of a total of 455 patients).~Exclusion Criteria:~* Recurrent tonsillitis~* Craniofacial syndromes~* Neuromuscular disorders~* Sickle cell disease

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 14 Years
- Healthy Volunteers: f

Study Arms:
- Children who underwent PITA (Type: None): Children who underwent partial intracapsular tonsillectomy and adenoidectomy between July 2003 and January 2008 for treatment of pediatric sleep-disordered breathing documented by positive preoperative polysomnography.
- Children who underwent T&A (Type: None): Children who underwent total tonsillectomy and adenoidectomy between July 2003 and January 2008 for treatment of pediatric sleep-disordered breathing documented by positive preoperative polysomnography.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Placebo or Bosentan to Treat Patients With Single Ventricle Physiology.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* TCPC operated~* Age \> 15 years old~* Clinical stability \> 3 months, evaluated by investigator from clinical record~* For women: Negative s-hCG and use of contraception~Exclusion Criteria:~* Severe heart failure (NYHA-class IV)~* Oxygen saturation \< 85 % at rest~* Pre-existing liver condition (transaminases 2x \> reference)~* Renal failure (creatinin \> 150 mmol/l)~* Obstruction of TCPC circulation~* History of work induced severe arrhythmia~* Systolic blood pressure below 80% of reference (BT \< 88 mmHg)~* Use of any of following drugs: Fluconazol, Ketoconazole, CiclosporinA, Lopinavir, Ritonavir, Rifampicin, Carbamazepin and Phenytoin~* Significant extra-cardiac condition e.g. neurological impairment

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bosentan (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Belimumab in Subjects With Systemic Lupus Erythematosus (SLE)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~* Clinical diagnosis of SLE by ACR criteria.~* Active SLE disease.~* Autoantibody-positive.~* On stable SLE treatment regimen.~Key Exclusion Criteria:~* Pregnant or nursing~* Have received treatment with any B cell targeted therapy.~* Have received treatment with a biological investigational agent in the past year.~* Have received IV cyclophosphamide within 180 days of Day 0.~* Have severe lupus kidney disease.~* Have active central nervous system (CNS) lupus.~* Have required management of acute or chronic infections within the past 60 days.~* Have current drug or alcohol abuse or dependence.~* Have a historically positive test or test positive at screening for HIV, hepatitis B, or hepatitis C.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo
- Belimumab 1 mg/kg (Type: EXPERIMENTAL): Belimumab 1 mg/kg
- Belimumab 10 mg/kg (Type: EXPERIMENTAL): Belimumab 10 mg/kg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Internet-based Behavioral Pain Management

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Presence of at least a moderate level of chronic low back pain (i.e., numeric rating scale pain scores of 4) and presence of low back pain for a period of 3 months;~* Availability of a computer with Internet access;~* Indication of the preparation, action, or maintenance stage of readiness to change on a brief five item staging checklist and a rating of at least 4 or greater on a 0 (not at all interested) to 10 (extremely interested) rating scale designed to ensure participants' interest in receiving pain self-management via the Internet;~* Veteran receiving care at VA Connecticut Healthcare System~Exclusion Criteria:~* life threatening or acute medical condition that could impair participation (e.g., severe COPD, lower limb amputation, terminal cancer);~* psychiatric condition (e.g., active substance abuse, psychosis or suicidality) that could impair participation~* surgical interventions for pain during their participation in this study~* sensory deficits that would impair participation (e.g., visual impairment affecting ability to navigate Internet-based intervention).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 10 week Pain EASE access (Type: EXPERIMENTAL): behavioral pain self-management intervention (Pain EASE) delivered via the Internet

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Bone Marrow Mononuclear Cells vs Mesenchymal Stem Cells in Diabetic Patients With Chronic Limb Ischemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Adult male or female, 40 years of age or over (until 85 years old)~* TcPO2 ≤ 30 mmHg.~* Diagnosis of diabetes.~* Patients with signs of critical ischemia such as (i) ulcer that does not heal, (ii) necrosis or loss of tissue, (iii) pain at rest, and (iv) intermittent claudication.~* Basal Rutherford classification stage 3 to 5.~* Non-revascularizable patients due to comorbidities and/or anatomy.~* Patients that despite revascularization (vascular surgery), have adequate distal beds to perfuse the limb.~* Ankle/brachial index less than 0.4.~* Stenosis or occlusion of the infrapatellar arteries.~Exclusion Criteria:~* Participants that do not sign the informed consent.~* Presence of osteomyelitis.~* Hemodynamic instability (MAP\<65 mmHg or vasopressor requirement).~* Any acute systemic infectious disease process.~* Severe sepsis.~* Uncontrolled coagulopathy.~* Condition of cancer.~* Use of immunosuppressive or cytotoxic drugs~* Alterations of the bone marrow that do not allow the adequate extraction of the components to be used as: acute leukemia, chronic leukemia, marrow aplasia, myelodysplastic syndrome, and myelophthisis.~* Contraindication of sedation for bone marrow aspirate.~* Patients who have suffered in a period \< six months of myocardial infarction, disease cerebrovascular or coronary intervention.~* Patients with liver failure indicated by serum transaminases (aspartate aminotransferase and alanine aminotransferase), with values twice the normal limit.~* Any acute or chronic contagious disease including hepatitis B, hepatitis C, and HIV.~* Any other comorbidity that the treating vascular surgeon considers as a contraindication to cell treatments.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Placebo group (Type: PLACEBO_COMPARATOR): Placebo group (n=10), which consisted of 15 injections of 1 mL of vehicle (1 mL saline solution with 2% of autologous serum) on periadventitial arteries in one dose at day 0.
- Auto-BM-MNC (Type: EXPERIMENTAL): Auto-BM-MNC (n=7) were obtained from diabetic patients. Fifteen injections of 7.197x106 ± 2.984x106 cells/mL each with 2% of autologous serum were periadventitial arteries administrated in one dose at day 0.
- Allo-WJ-MSCs (Type: EXPERIMENTAL): Allo-WJ-MSCs (n=7) were obtained from culturing the WJ from healthy cordon umbilical donors unrelated to the patient. Fifteen injections of 1.333x106 cells/mL each with 5% of human serum albumin serum were periadventitial arteries administrated in one dose at day 0.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Safety and Effectiveness of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Plaque-type Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with plaque-type psoriasis diagnosed at least 6 months prior and covering at least 10% of total body surface areas~* Have psoriasis area-and-severity index score of \>=12~* Patients who are considered by treating dermatologist to be a candidate for phototherapy or systemic treatment of psoriasis~* Have no history of latent or active TB~Exclusion Criteria:~* Currently have nonplaque forms of psoriasis or drug-induced psoriasis~* Have any therapeutic agent targeted at reducing IL-12 or IL-23~* Have had a BCG vaccination within the previous 12 months~* Have a history of chronic or recurrent infectious disease or who have or have had a serious infection requiring hospitalization or intravenous antibiotics within the previous 2 months~* Have or ever have had a nontuberculous mycobacterial infection or opportunistic infection~* Patients known to be infected with human immunodeficiency virus, hepatitis B, or hepatitis C~* Have current signs or symptoms of severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, cardiac, neurologic, cerebral, or psychiatric disease~* Patients with a malignancy or who have a history of malignancy (with the exception of certain skin cancers and pre-invasive cervical cancer)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ustekinumab 45 mg (Type: EXPERIMENTAL): Patients received ustekinumab 45 mg at Weeks 0, 4 and 16. Treatments after Week 16 were dependent on clinical response. At Week 40, patients who achieved PASI 75 at both Week 28 and Week 40 were re-randomized to withdraw from therapy (placebo) or continue 45 mg every 12 week maintenance therapy.
- ustekinumab 90 mg (Type: EXPERIMENTAL): Patients received ustekinumab 90 mg at Week 0, 4 and 16. Treatments after Week 16 were dependent on clinical response. At Week 40, patients who achieved PASI 75 at both Week 28 and Week 40 were re-randomized to withdraw from therapy (placebo) or continue 90 mg every 12 week maintenance therapy.
- Placebo (Type: PLACEBO_COMPARATOR): Patients received placebo at Weeks 0 and 4. At Weeks 12 and 16, placebo crossed over to receive ustekinumab 45 mg or 90 mg. Treatments after Week 16 were dependent on clinical response.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Acceptability of Low-Residue Diet Package (Enimaclin®) as Diet Control Before Colonoscopy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female~* Outpatient or healthy volunteer for health examination, 20\~75 years old~* Eligible for oral bowel preparation~* BMI (Body Mass Index) ≤ 30~Exclusion Criteria:~* Patients with severe constipation (as fewer than three stools per week)~* Patients with bowel obstruction~* Patients contraindicated with treatment drug~* Patients who need emergency medication~* Ineligible for bowel preparation~* Pregnant or breast-feeding~* Patients with known allergies to treatment drug or low-residue diet package~* Patients who are ineligible to enroll

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- low-residue diet package (Enimaclin®) (Type: EXPERIMENTAL): Low-residue diet package with normal amount 2L PEG-ELS
- Self-controlled diet (Type: PLACEBO_COMPARATOR): Self-controlled diet with normal amount of 2L PEG-ELS
- Low-residue diet (Enimaclin®) package (Type: EXPERIMENTAL): Low-residue diet package with low volume 1.5L PEG-ELS

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Trigger-point Blockade in Persistent Pain After Open Groin Hernia Repair

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with persistent pain (\< 6 mo) after open groin hernia repair~* Patients with maximal pain area 3 cm or less from the superficial inguinal ring~* Patients living in the Capital Region of Denmark (Region Hovedstaden) or the Region of Zealand (Region Sjælland)~Exclusion Criteria:~* Known allergy to bupivacaine or other local anesthetics of amide-type~* Declared incapable of making his/hers own affairs~* Does not comprehend Danish in the written or spoken language~* Cognitive impairment to a degree influencing the testing reliability~* Known recurrence of the inguinal hernia~* Other surgical procedures performed in the groin or on the external genitals~* Neuropathy affecting the groin region caused by other conditions, e.g. post-stroke, multiple sclerosis, herniated intervertebral disc~* Abuse of alcohol or drugs~* Unable to cooperate with the sensory examinations

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Bupivacaine (Type: EXPERIMENTAL): injection, 25 mg, once, 5 min
- Placebo (Type: PLACEBO_COMPARATOR): injection, 10 ml 0.9% sodium chloride, once, 5 min

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: To Evaluate the Safety and Tolerability of Combined Administration of SHR2285 Tablets With Aspirin, Clopidogrel or Ticagrelor in Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Healthy subjects, aged 18-55 (including boundary);~2. Body mass index (BMI) between 19 to 28 kg/m2 (including boundary), male body weight ≥50 kg and \<90 kg , female body weight ≥45kg and \<90kg;~3. Participant with no clinically significant findings in vital signs, physical examination, 12-lead ECG ,X-ray and laboratory parameters，etc.~4. Understand the study procedures and methods, voluntary to participate in the study and signed the informed consent.~Exclusion Criteria:~1. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) or total bilirubin/direct bilirubin \> 1.2 fold ULN during screening/baseline.~2. Serum creatinine\> ULN during screening/baseline.~3. Positive faecal occult blood~4. Abnormal coagulation function.~5. A clinical history of coagulation dysfunction; subjects with adverse reaction of antiplatelet drugs or anticoagulant drugs.~6. Subjects with severe head trauma or head surgery within 2 years or surgery within 3 months prior to the screening.~7. Blood donation or blood loss within 1 month≥200 mLor≥400 mL within 3 months before administration.~8. Human immunodeficiency virus antibody, syphilis serological examination, hepatitis b virus surface antigen, hepatitis c virus antibody were positive.~9. 3 months prior to screening involved in any drug or medical device clinical studies. .~10. Female subjects who did not receive contraception at least 30 days before administration and etc.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- group A： Aspirin + Clopidogrel + placebo or SHR2285 (dose 1) (Type: EXPERIMENTAL): None
- group B ：Aspirin + Clopidogrel + placebo or SHR2285 (dose 2) (Type: EXPERIMENTAL): None
- group C： Aspirin + Ticagrelor + placebo or SHR2285 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Transcranial Laser Therapy for Major Depressive Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* The subject is at least 18 years of age at screening, but has not had their 66th birthday.~* SCID diagnosis of major depressive disorder (Structured Clinical Interview for Diagnostic Statistical Manual-IV)~* HAM-D-17 \>14 and \< 25~* Women of child-bearing potential must use a double-barrier method for birth control (e.g. condoms with spermicide) if sexually active.~* Subject Informed Consent obtained in writing in compliance with local regulations prior to enrollment into this study.~* The subject (and caregiver, if applicable) is willing to participate in this study for at least 8 weeks.~* Subjects on an antidepressant will need to be on a stable dose for at least six weeks.~Exclusion Criteria:~* The subject is pregnant or lactating.~* The subject failed two or more FDA-approved antidepressants during current episode~* Subjects with less than 2 months MDD symptom free prior to current episode.~* The subject used targeted psychotherapies for depression during current episode (support therapy or counseling are allowed)~* Substance dependence or abuse in the past 6 months~* Psychotic disorder or psychotic episode (current psychotic episode per SCID assessment)~* Bipolar affective disorder (per SCID assessment)~* Unstable medical illness, defined as any medical illness which has not been well-controlled with standard-of-care medications (e.g., insulin for diabetes mellitus, HCTZ for hypertension)~* Active suicidal or homicidal ideation, as determined by CHRT screening~* The subject has a significant skin condition (i.e., hemangioma, scleroderma, psoriasis, rash, open wound or tattoo) on the subject's scalp that is found to be directly below any of the procedure sites.~* The subject has an implant of any kind in the head (e.g. stent, clipped aneurysm, embolised AVM, implantable shunt - Hakim valve).~* Any use of light-activated drugs (photodynamic therapy) within 14 days prior to study enrollment (in US: Visudine (verteporfin) - for age related macular degeneration; Aminolevulinic Acid- for actinic keratoses; Photofrin (porfimer sodium) - for esophageal cancer, non-small cell lung cancer; Levulan Kerastick (aminolevulinic acid HCl) - for actinic keratosis; 5-aminolevulinic acid (ALA)- for non-melanoma skin cancer)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- TLT Treatment Group 1 (Type: EXPERIMENTAL): The TLT group will receive 2 near-infrared radiation via Transcranial LED Therapy (TLT) treatments per week for 8 weeks
- TLT Treatment Group 2 (Type: SHAM_COMPARATOR): The sham group will receive 2 treatments of the sham device per week for 8 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete